- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Navigating 5 Analyst Ratings For Arcus Biosciences | 2 | Benzinga.com | ||
| 20.03. | Arcus Biosciences COO sells over $240k in company stock | 5 | Investing.com | ||
| 22.02. | Earnings call: Arcus Biosciences reports strong Q4 results, plans for 2025 | 6 | Investing.com | ||
| 22.02. | Arcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7M | 2 | Seeking Alpha | ||
| 21.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.02. | Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update | 144 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
| 20.02. | Arcus Biosciences Q4 2023 Earnings Preview | 2 | Seeking Alpha | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval | 2 | Pharmaceutical Technology | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Extrahepatic Bile Duct Cancer: Likelihood of Approval | 2 | Pharmaceutical Technology | ||
| 19.02. | Zimberelimab by Arcus Biosciences for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval | 5 | Pharmaceutical Technology | ||
| 30.01. | Arcus Biosciences: Did Gilead Sciences overpay for its latest investment? | 13 | Seeking Alpha | ||
| 30.01. | CLS, CGEN and RCUS are among pre market gainers | 5 | Seeking Alpha | ||
| 30.01. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.01. | US STOCKS Super Micro Computer, Arcus Biosciences, Agape ATP | 7 | Reuters | ||
| 30.01. | Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soars | 6 | Benzinga.com | ||
| 30.01. | Arcus Biosciences surges after Gilead Sciences raises stake | 5 | Reuters | ||
| 30.01. | Gilead and Arcus Biosciences expand oncology partnership deal | 4 | Pharmaceutical Technology | ||
| 30.01. | Gilead Sciences Increases Stake In Arcus Biosciences To 33% | 489 | AFX News | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) has raised its stake in Arcus Biosciences Inc. (RCUS) to 33% to accelerate growth of their joint development programs that span multiple indications... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 52,25 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting | ||
| REGENERON PHARMACEUTICALS | 844,00 | -0,40 % | Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD | ||
| DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| EXELIXIS | 21,990 | -0,72 % | Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update | ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,839 | 0,00 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| BEAM THERAPEUTICS | 22,740 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 0,990 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,940 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,980 | -3,40 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,866 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,660 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,710 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,040 | -1,11 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,580 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen |
ARCUS BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,460 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
